GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Provided By GlobeNewswire
Last update: Sep 11, 2025
No decline in lung function observed at 6-week interim analysis
builds upon positive safety and biomarker data
Phase 2a study fully enrolled; Topline data on track for Q3 2025
Read more at globenewswire.com
